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Background: The aHUS patients with 
autoantibodies against CFH lack CFHR1. 
Results: The autoantibody epitope was mapped 
and the structure of the corresponding part of 
CFHR1 was solved. 
Conclusion: The structural difference between 
the autoantigenic epitope of CFH and its 
homologous site in CFHR1 holds the key to the 
formation of autoantibodies in CFHR1 deficient 
aHUS patients. 
Significance: A plausible explanation of the 
CFHR1 deficiency in autoimmune aHUS 
obtained 
 
ABSTRACT 
 Atypical hemolytic uremic syndrome 
(aHUS) is characterized by complement 
attack against host cells due to mutations in 
complement proteins or autoantibodies 
against the complement regulator factor H 
(CFH).  It is unknown why nearly all the 
patients with autoimmune aHUS lack CFH- 
related protein-1  (CFHR1).  These patients 
have autoantibodies against CFH  domains 
19-20 (CFH19-20)  which  are nearly  identical  
to CFHR1  domains 4-5  (CFHR14-5).  Here, 
binding site mapping of autoantibodies from 
seventeen patients using mutant CFH19-20  
constructs revealed an autoantibody epitope 
cluster within a loop on domain 20, next to 
the buried two residues different in CFH19-20  
and CFHR14-5. Crystal structure of CFHR14-5 
revealed difference in conformation of the  
autoantigenic  loop  on  the  carboxyl-
terminal  domains  of  CFH  and  CFHR1  
explaining variation  in  binding  of  
autoantibodies  from  some  aHUS  patients  
to  CFH19-20   and  CFHR14-5. The 
autoantigenic loop on CFH seems to be 
generally flexible as its conformation in 
previously published structures   of CFH19-20  
bound to a microbial protein OspE and a  
sialic acid glycan is somewhat altered. 
Cumulatively our data suggest that 
association of CFHR1 deficiency with 
autoimmune aHUS could be owing to its 
structural difference to the autoantigenic 
CFH epitope suggesting a novel explanation 
for CFHR1 deficiency in pathogenesis of 
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autoimmune aHUS. 
 
INTRODUCTION 
aHUS is a  rare and often fatal systemic 
disease, characterized by hemolytic anemia, 
thrombocytopenia, microvascular thrombosis, 
and kidney failure (1). It is associated with 
dysregulation of complement activation via either 
mutations, polymorphisms, or rearrangements in 
genes coding for various complement proteins 
(2). The mutations are mainly found in the gene 
coding for the complement regulator CFH (3,4), 
which mediates elimination of the central 
complement activation component C3b. We and 
others have shown how mutations in CFH19-20 
cause impaired regulation of C3b on host cells 
leading to complement attack against red blood 
cells, platelets, and endothelial cells as seen 
clinically in aHUS (5-8). Some aHUS cases, 
however, are caused by autoantibodies against 
CFH (CFH-AA). These antibodies have been 
identified in 5–11% of aHUS patients in different 
cohorts (9-13) but even 56% of 246 HUS patients 
have been reported with CFH-AA in India(14). 
Patients with the autoimmune form of aHUS 
nearly always lack certain CFH-related proteins, 
primarily CFHR1(10,15).  
CFH and CFHRs are encoded by 
adjacent genes and form a protein family 
(supplemental Fig. S1)(16). CFHRs are 
composed of four to nine complement control 
protein (CCP) domains, also called short 
consensus repeats, and especially the two most 
carboxyl-terminal domains have relatively high 
sequence homologies with the carboxyl-terminal 
domains of CFH (supplemental Fig. S1)(16).  
There are only two residues different in the last 
two carboxyl terminal domains of CFH and 
CFHR1 (domains 19-20 and 4-5, respectively). 
The functional importance of these minor 
differences is obvious since the hybrid 
CFH/CFHR1 genes producing fusion proteins 
CFH1-18/CFHR14-5 or CFHR11-3/CFH19-20 have 
been found in aHUS patients in the absence of 
other mutants or CFH-AA(4,17-19). The domains 
19-20 of CFH are responsible for directing its 
complement regulatory activity to cell and 
extracellular matrix surfaces by binding 
simultaneously to both C3b and negatively 
charged glycosaminoglycans or sialic acid 
glycans on the surfaces (6,20,21). The 
autoantibodies of nearly all the patients with 
autoimmune aHUS recognize the carboxyl-
terminus of CFH, and inhibit the physiological 
CFH-mediated protection of host cells from 
complement attack(10,11,13,22,23). 
More than 90% of the patients with CFH-
AA lack CFHR1 and CFHR3, resulting from a 
homozygous deletion of the genomic region 
containing both of them(10,12,13,15). Some 
patients have other rarer genetic alterations, 
including homozygous CFHR1/CFHR4A deletion 
(12), a combination of  heterozygous 
CFHR1/CFHR3 and CFHR1/CFHR4A deletions 
(12,13), or a combined heterozygous 
CFHR1/CFHR3 deletion in the presence of a 
missense mutation in CFHR1 (12). The common 
feature in all these genetic alterations is the 
deficiency of CFHR1 (24,25). However, CFH-
AAs have also been described, although rarely, in 
patients having two normal copies 
of CFHR1 and CFHR3 but mutations 
in CFH, CFI, CD46, or C3 (12,13). CFH-AAs 
often cross-react with CFHR1 (13,23,26) but the 
exact location of the autoantibody site on CFHR1 
has not been shown. On the basis of inhibition of 
autoantibody binding to CFHR1 by the mAb 
C18(26) and the sequence homology to the 
carboxyl-terminus of CFH it is, however, likely 
that the autoantibody binding site is within the 
last two domains of CFHR1, i.e. far away from 
its N-terminal dimerization site(27). 
The reason for the association between 
CFH-AA and the CFHR1 deficiency has not been 
known till date. In this study we aimed at solving 
why deficiency of one molecule (CFHR1) 
predisposes to autoimmunity against another, 
highly homologous, molecule (CFH) in aHUS. 
We mapped the binding sites of CFH-AA within 
CFH19-20 and compared the CFH-AA binding 
sites to the previously reported ligand binding 
sites on CFH19-20. Since the autoantibody epitopes 
formed a cluster next to the residues that are 
different in the two carboxyl-terminal domains of 
CFH and CFHR1, we decided to solve and 
analyze the structure of CFHR14-5 and study the 
potential differences in antigenicity of those two 
molecules. We found structural differences in the 
autoantibody binding site of CFH domain 20 and 
the corresponding homologous site of CFHR1 
domain 5. Based on these data a novel model is 
proposed hereby suggesting how immunization 
against CFH domain 20 could be linked to 
CFHR1 deficiency.  
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EXPERIMENTAL PROCEDURES 
Proteins: Cloning, expression and purification of 
the wild type (WT) and mutant CFH19-20 proteins 
with the 14 single point mutations have been 
described earlier(5,7,28). Proper folding of the 
constructs has been verified for three mutants 
(Q1139A, R1203A and the double mutant 
D1119G/Q1139A) by solving the structures using 
X-ray crystallography(6,28,29) and for five 
mutants (R1182A, W1183L, K1188A, E1198A, 
and R1206A) by circular dichroism(30).  
CFHR14-5 was generated by site directed 
mutagenesis of CFH19-20 encoding DNA in 
pPICZαB vector (Invitrogen). The primer used to 
introduce the S1191L and V1197A mutations 
was CAG AAG CTT TAT TTG AGA ACA TCA 
GGT GAA GAA GCT TTT GTG. The mutations 
were confirmed by sequencing before expression 
of CFHR14-5 in Pichia pastoris (strain X-33) 
using 1% methanol induction as described 
previously(7). 
Recombinant CFHR1, CFH1-7, CFH8-14, 
CFH15-20 and CFHR4B were generated as 
described earlier(31,32). 
CFH was bought from Merck 
Biosciences (Schwalbach, Germany). The mAb 
C18(33) was purchased from Enzo Life Sciences 
(Lörrach, Germany). 
Patients and blood samples: The studies have 
been approved by the Research Ethics Committee 
of the Medical Faculty of Friedrich Schiller 
University and were performed in accordance 
with the Declaration of Helsinki. 
Patients with aHUS were screened for 
CFH-AA using ELISA as described(9,11). All 
patients lacked the CFHR1 and CFHR3 genes 
and proteins except for patient 2, who had two 
copies of both genes, and patient 10 who carries a 
homozygous CFHR1 deletion and is 
heterozygous for CFHR3. Three of the patients 
(patients 3, 7 and 8) have previously been 
described(22). Features of the used 17 patient 
sera containing CFH-AA are summarized in 
supplemental Fig. S2. 
Microtiter plate assays: WT or mutant CFH19-20 
proteins (5 µg/ml) were coated to Nunc 
MaxiSorp plates (Thermo Scientific). Binding of 
patient sera (1:50-1:200 depending on the 
antibody titer) was analyzed as described11. 
Binding of mAb C18 (5 µg/ml) was detected 
using peroxidase-conjugated swine anti-mouse 
IgG. 
 Binding of the patient CFH-AA (sera 
diluted 1:100) to CFH, its recombinant 
fragments, CFHR1 and CFHR14-5 was compared 
as above using 250 nM immobilized recombinant 
proteins, plasma purified CFH (65 nM), or 
recombinant CFHR4B and albumin as negative 
controls (Fig. 2). Relative binding was calculated 
from representative datasets performed in 
triplicates. 
 The assay comparing binding avidity of 
CFH19-20 and CFHR14-5 with the purified IgG of 
the patient 11 was done after coating CFH19-20 (10 
µg/ml) to Nunc MaxiSorp plates. After blocking 
(0.05% Tween-20 in PBS) for 120 min and 
washes (0.02% Tween-20 in PBS), 40 µl of 
patient IgG (3.8 µg/ml) and CFH19-20, CFHR14-5, 
or CFH5-7 was added in different dilutions and 
incubated for 120 min at 37oC followed by 
measuring IgG binding as described11. The 
experiment was performed three times in 
triplicates and the background subtracted data 
was normalized using the values obtained without 
an inhibitor (100% binding). 
Crystallization and solving the CFHR14-5 
structure: CFHR14-5 was crystallized at 293 K 
from hanging drops in the presence of 2 M 
ammonium sulphate and 0.1 M sodium acetate at 
pH 4.6. The cube shaped crystals appeared within 
5 days and were cryo-protected by 25% glycerol 
(supplemented by the mother liquor). The 
diffraction data (to 2.9Å) were collected at the 
ESRF ID14-4 beamline (34) at 100K on a CCD 
ADSC Q315r detector at 0.979520 Å. The data 
were indexed and scaled using XDS (35).  The 
structure of the CFH19-20 mutant R1203A (PDB 
code 3KZJ,(28)) was used as a search model in 
Phaser(36), and two molecules of CFHR14-5 were 
identified in the asymmetric unit. After 
successive rounds of model building with 
Coot(37) and refinement in real space using 
‘phenix.refine’ software(38) we could refine the 
structure to a higher precision than the initial 
model (Rwork/Rfree = 0.20/0.26; supplemental Fig. 
S3). The last refinement cycles were done using 
TLS parameters (10 TLS groups). In the 
Ramachandran plot, 95% of the amino acid 
structures were within the most favoured region.  
The superpositions of different structures 
and structural illustrations were prepared using 
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Pymol software (Schrödinger, Portland, USA). 
The surface charge distribution of both the 
molecules CFHR14-5 and CFH19-20 was calculated 
using APBS(39) and the potentials on the solvent 
accessible surfaces were displayed in Pymol.  
Coordinates and structure factors are 
available from the RCSB Protein Data Bank 
(http://www.pdb.org). The accession number is 
4MUC for the crystal structure of the CFHR14-5.  
Statistical analyses. Values are expressed as 
means ± SEM using GraphPad Prism software 
(version 6, La Jolla, CA). All curves and bar 
diagrams were made using the same software. 
RESULTS 
Mapping of the autoantibody binding residues 
on CFH19-20. Binding of IgG from sera of 17 
aHUS patients with CFH-AA to 14 different 
CFH19-20 mutants was tested (Fig. 1A). The 
binding data indicated a congruent tendency as 
follows. The binding of IgG from all the patients 
to the L1189R mutant was diminished at least 
30% when compared to the wildtype (WT) 
CFH19-20. IgG from fourteen patients showed at 
least 30% impaired binding to the E1198A 
mutant, and IgG from ten or eleven patients 
showed impaired binding to the CFH19-20 mutants 
T1184R, K1186A, and K1188A when compared 
to WT CFH19-20 (Fig. 1B). Binding of IgG from 
one to three patients was impaired to the 
D1119G, Q1139A, R1182A, W1183L, or 
R1210A mutants while binding of IgG from all 
the patients was similar to WT CFH19-20 and the 
mutants W1157L, R1203A, R1206A, and 
R1215Q (Fig. 1B).  
We also found that binding of the 
monoclonal antibody C18, which has previously 
been shown to have an epitope overlapping with 
that of several CFH-AAs(11,22), was diminished 
to the K1186A mutant (Fig. 1A). This antibody 
could efficiently inhibit binding of autoantibodies 
to CFH19-20 from also those four individuals 
(patients 10, 11, 12, and 14) whose 
autoantibodies showed only moderately impaired 
binding to the five CFH mutants to which binding 
of autoantibodies from most of the patients was 
clearly impaired (data not shown). This indicates 
that the main binding site of the autoantibodies 
from also those patients is likely to be 
overlapping. 
 
The autoantibody-binding site overlaps with 
the heparin and common microbial binding 
sites. Our previously solved crystal structure of 
CFH19-20(7) was used to visualize location of the 
five residues of CFH19-20 (T1184, K1186, K1188, 
L1189, and E1198) each of which were found to 
be involved in binding of CFH-AA from at least 
10 out of 17 patients. These residues form a 
tightly packed cluster (diameter of approx. 11 Å) 
on one side of CFH domain 20 termed the “CFH-
AA site” on domain 20 (Fig. 1C). When 
compared to the previously described functional 
sites on CFH19-20 the CFH-AA site was clearly 
distinct from the two sites for C3b or C3d on 
domains 19 and 20(6,20) but adjacent to and 
partially overlapping with the site involved in 
binding of CFH to heparin and endothelial 
cells(5,40) (Fig. 1D) as well as the recently 
described common microbial binding site on 
CFH domain 20(29,30) (Fig. 1E).  
Binding of anti-CFH autoantibodies to the 
CFHR1 carboxyl-terminus. On the basis of the 
previously solved structure of CFH19-20, the two 
residues that are different in CFH19-20 and 
CFHR14-5 (S1191 and V1197 of CFH) are buried 
beneath the identified CFH-AA site. Therefore 
we studied whether the difference of the two 
amino acids in the carboxyl-terminal domains of 
CFH and CFHR1 had an influence on binding of 
autoantibodies from the patient sera. The level of 
binding of antibodies from various patient sera to 
both CFH19-20 and CFHR14-5 varied from patient 
to patient and this seemed to correlate to the 
antibody titer in the sera (Fig. S2). IgG from 
eight out of the ten CFH-AA patient samples that 
we had available enough for the analysis bound 
similarly to CFHR14-5, CFH, and CFH19-20, while 
binding of autoantibodies from two of the 
samples (patients 2 and 9) was diminished to 
CFHR14-5 (Fig. 2 A-C). Next purified IgG 
fraction of the patient 11 was used to compare 
affinities of the autoantibodies to CFH19-20 and 
CFHR14-5 using an inhibition assay. Binding of 
IgG was somewhat stronger to CFH in this assay 
(Fig. 2D, E) although a clear difference in 
binding to CFH19-20 and CFHR14-5 could not be 
detected in the ELISA assay (Fig. 2B, C). Taken 
together, the results on difference in binding of 
CFH-AA to CFH19-20 and CFHR14-5 indicated that 
the conformation of the CFH-AA site needs to be 
slightly different in CFH domain 20 and CFHR 
domain 5.  
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Structures of the carboxyl-termini of CFHR1 
and CFH are nearly identical.  
To detect possible differences in the CFH-AA 
site on CFH19-20 and the corresponding site on 
CHFR1 we used X-ray crystallography to solve 
the structure of CFHR14-5. The structure was 
obtained as a homodimer at 2.9 Å resolution from 
a different space group (P622) than the 
previously published CFH19-20 structures 
(I4122)(7,28) (supplemental Fig. S3) but the 
structures aligned very well to each other (Fig. 
3A). Superimposing the CFHR14-5 structure with 
the previously published structures of CFH19-20 
solved either as homotetramers (7), in complex 
with C3d (6), or in complex with the borrelial 
OspE protein (29) gave root mean square 
deviation (RMSD) of 0.5-1.1 Å for the 113 
aligned Cα atoms, indicating that the structures 
were nearly identical. Also the charge potentials 
on the solvent accessible surface displayed at ±2 
kT/e level on CFHR14-5 and CFH19-20 were similar 
all around the molecules (Fig. 3B).  
Differences noticed in the structure of the 
CFH-AA site of CFH19-20 and CFHR14-5. The 
structures of CFH19-20 and CFHR14-5 were 
seemingly identical but the detailed tertiary 
structure of the buried region containing the 
mutations S1191L and V1197A was naturally 
somewhat different (Fig. 3C). In addition, as 
expected on the basis of the differences observed 
in binding of certain autoantibodies and the 
previously reported functional differences of 
CFH/CFHR1 hybrid proteins, also the 
conformation of the CFH-AA site on CFHR14-5 
was slightly different from that on CFH19-20 
(RMSD of backbone atoms of the loop region is 
3Å); both the backbone and loops forming the 
CFH-AA site (R281-L288 of CFHR1 and R1182-
L1189 of CFH, respectively) had a different 
orientation (Fig. 3D). The main difference in the 
backbone is formation of a short α-helix in the 
loop of CFHR14-5 while no prominent helix has 
been seen in this region in any of the solved 
structures of CFH19-20. The orientation of some of 
the side chains was also clearly different as all 
the residues from R281 through L288 of 
CFHR14-5 were distinctively apart from the 
location of side chains of the corresponding 
residues of CFH19-20 (from R1182 through 
L1189) (Fig. 3D). Interestingly only one of the 
two CFHR14-5 molecules in the same crystalline 
space showed the conformation that was 
dissimilar to the CFH-AA site on CFH domain 20 
while the other CFHR14-5 molecule had the site 
similar to CFH. Since this indicated that the loop 
R281 through L288 of CFHR1 is flexible (or has 
two conformations), we next analyzed whether 
flexibility could be observed in the CFH-AA site 
of the previously published structures of CFH19-
20. Conformation of the loop R1182 through 
L1189 was somewhat different in free CFH19-20 
compared to the mutually similar conformation of 
CFH19-20 in complex with either the microbial 
protein OspE (RMSD of the backbone of the loop 
residues: 2.7 Å), or the natural ligands C3d 
(RMSD of the backbone of the loop residues: 3.0 
Å) or sialic acid glycan (RMSD of the backbone 
of the loop residues: 2.9 Å) (Fig. 3E, F). This 
conformation was also different from that of 
CFHR1 (RMSD of the backbone of the loop 
residues 3.0 Å). This indicates structural 
flexibility of the CFH-AA site upon binding of a 
ligand to the same domain (Fig. 3 E, F).  
In order to exclude potential 
misinterpretation of the X-ray diffraction data of 
the CFH-AA site, we next compared the electron 
density maps (2mFo-DFc) of R1182-L1189 of 
CFH19-20 (7) and R281-L288 of CFHR14-5 (Fig. 
4). Clearly the model of CFHR14-5, but not of 
CFH19-20, fits very well with the electron density 
map of CFHR14-5 in this region (Fig. 4A, B) 
while the corresponding region in the model of 
CFH19-20, but not of CFHR14-5, fits well into the 
electron density map of CFH19-20 (Fig. 4C, D). 
The real space correlation coefficients along with 
the B-factors of the above mentioned residues 
also showed normal behavior (supplemental Fig. 
S4) and there were no crystal contacts within this 
region in either the CFHR14-5 or CFH19-20 
structures. 
DISCUSSION 
Autoimmune-aHUS is an unusual 
autoimmune disease since it is associated with 
deficiency of a protein (CFHR1) homologous to 
the autoantigen (CFH). Therefore it offers an 
exceptional opportunity to study phenomena 
leading to antibody-associated autoimmunity. 
This study shows that the amino acid residues 
contributing to the binding sites of CFH-AA from 
seventeen patients with autoimmune aHUS form 
a cluster on domain 20 of CFH adjacent to the 
common microbial binding site. The differential 
binding of CFH-AA from two aHUS patient to 
CFH19-20 and CFHR14-5, as also hinted 
previously(13,26), and the small but clear 
differences in the X-ray crystal structures of the 
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loop forming the autoantigenic epitope on CFH 
and CFHR1 indicate that the C-terminal domain 
of CFH and CFHR1 can have slightly different 
conformations. In addition, the conformation of 
the autoantigenic loop on CFH seems flexible 
since we noticed that the loop conformation is 
slightly different after binding of ligands to 
domain 20 or CFH in the previously published 
structures (21,29). The explanation why CFHR1 
deficiency is associated with aHUS has been 
unexplained but the new results enabled an 
evaluation of the previously suggested and 
generation of a new hypothesis of induced 
autoantigenic neoepitope as an explanation for 
the association between CFHR1 deficiency and 
autoantibody formation against the common 
CFH-AA epitope on domain 20.  
aHUS-associated mutations in the 
carboxyl-terminal domains of CFH have been to 
cause reduced binding of CFH to C3b or host cell 
surface structures such as glycosaminoglycans / 
heparin (5-7,41-43). aHUS-associated 
autoantibodies against CFH19-20 cause 
uncontrolled complement attack against host cells 
and autoantibodies from some patients have been 
shown to impair CFH binding to C3b or to host 
cells (11). Location of the CFH-AA binding site 
we identified on domain 20 indicates that the 
autoantibodies are likely to block binding of CFH 
at least to glycosaminoglycans/heparin, owing to 
proximity of the CFH-AA site to the heparin-
binding site. In addition, the location of the 
hemolysis-inducing aHUS mutation W1183L 
(26,44) next to the CFH-AA site (Fig. 3D) 
indicates the importance of the site in protecting 
host cells from complement. Although the C3b 
binding sites on CFH domains 19 and 20(6,20) 
are relatively distant from the CFH-AA binding 
site, the CFH-AAs might interfere with C3b 
binding owing to their large size as has been 
reported with the C18 mAb that we now and 
previously found to bind to the same region as 
the CFH-AAs (11)(Fig. 1A). Diminished binding 
of CFH to either the cell surface structures or 
C3b can lead to compromised protection of the 
plasma exposed host cells which has been 
reported widely in aHUS patients (1).  
Upon close comparison of the 
conformation of the autoantigenic loop of CFH in 
the published crystal and NMR structures of 
CFH19-20 (6,7,20,21,29,40,45) minor differences 
were noticed in the R1182-L1189 region of 
CFH19-20 in complex with OspE (29), C3d (6), or 
a sialic acid glycan (21). RMSD of backbone 
atoms of the loop region was 2.7-3.0 Å when 
compared to CFH19-20 alone (Fig. 3 E, F) Binding 
of CFH19-20 to heparin tetrasaccharide has also 
been shown to cause chemical shift perturbations 
in NMR at the CFH-AA site (21,40). Taken 
together, it is likely that the conformation of the 
region is somewhat flexible. It seems possible 
that the corresponding site on CFHR1 is also 
structurally flexible since amongst the two 
monomers in the unit cell of the CFHR14-5 crystal 
conformation of the CFH-AA site of one 
monomer was similar to CFH and one was 
different (Figures 3 and 4). The key difference 
between CFH and CFHR1 could therefore be that 
CFHR1 takes the alternate conformation 
spontaneously while, on the basis of various 
crystal and NMR structures, CFH19-20 takes a 
slightly altered conformation only upon binding 
of a ligand.  
In the case of CFHR14-5, the difference 
with the CFH19-20 structure being a crystal artifact 
is unlikely due to four reasons. First, only one of 
the monomers in a unit cell containing two 
CFHR14-5 molecules showed the structure which 
is considerably different from CFH domain 20 
(see the PDB entry 4MUC) indicating structural 
flexibility in that loop of domain 5 of CFHR1. 
Second, there were no direct contacts found 
between the residues of the CFH-AA site (R281-
L288) and the molecule in the neighboring 
crystal cell. Third, CFH-AA from two of the 
studied 10 patients bound differently to CFH19-20 
and CFHR4-5 (Fig. 2C) indicating that there is a 
difference within the CFH-AA binding site of 
these molecules. Fourth, CFHR14-5 and CFH19-20 
have been reported to have functional difference 
(45), which is obvious since the fusion proteins 
CFH1-18/FHR-14-5 and CFHR11-3/CFH19-20 are 
associated with aHUS and have different 
functions from the normal full length CFH and 
CFHR1 (4,17-19). Since domain 19 of CFH and 
domain 4 of CFHR1 are identical it is deduced 
that the difference leading to the clinical disease 
is within the terminal domain of the fusion 
proteins leading to the inability to control 
complement on self surfaces (18). Our results 
suggest that the reason for the functional 
difference between the most carboxyl-terminal 
domains of CFH and CFHR1 is in their varied 
ability to bind to heparin or glycosaminoglycans 
on self cells since the loop which has different 
conformation in CFH and CFHR1 contains 
several of the heparin binding residues(5,40) 
(Fig. 1C, D and 3D).  
  
Structural insight on CFHR1 deficiency in AI-aHUS

Nearly all the patients with CFH-AA lack 
CFHR1 (12,13), and thus it is likely that the 
absence of CFHR1 imparts the risk of the CFH-
AA generation. The risk for anti-CFH 
autoimmunity in the absence of CFHR1 is very 
high as the odds ratio is 442 (15). In this report 
we provide data for a structure-based molecular 
explanation to the phenomenon. The explanation 
is based on four observations in the current study. 
First, the binding sites of CFH-AA from the 17 
analyzed individuals formed clearly a cluster, the 
CFH-AA site. Second, the CFH-AA site in CFH 
domain 20 is adjacent to the two buried residues 
(S1191 and V1197) that are different between 
CFH19-20 and CFHR14-5. Third, although the 
crystal structures of CFHR14-5 and CFH19-20 are 
similar owing to the 98.5% sequence identity 
between them there is a small structural 
difference exactly at the CFH-AA site on the loop 
R1182-L1189 of CFH  (Fig. 3A, D). Fourth, a 
small conformational change has been detected 
within the autoantigenic loop upon binding of 
CFH19-20 to a microbial protein (29), a sialic acid 
glycan (21), heparin, or C3d. 
The two usual models to explain 
autoantibodies in general, an analogous epitope 
and a co-epitope model, are unable to explain the 
association of CFHR1 deficiency and CFH-AA 
binding to the CFH-AA site on domain 20. Thus, 
on the basis of the new data, we propose a novel 
explanation for the association of CFHR1 
deficiency with the autoimmune disease. In this 
model, called the “induced neoepitope model”, 
normal structure of the loop R1182-L1189 of 
CFH can be turned into an autoantigenic 
conformation upon induction by one or several 
ligands binding to that region of CFH domain 20 
(Fig. 5). It has been reported that several kinds of 
infections can precede the autoimmune aHUS 
and this is concordant with our model since 
several microbial molecules are known to bind 
close to the autoantigenic epitope of CFH(29,30) 
and we observed from previously published data 
that CFH19-20 in complex with OspE (29) has 
slightly altered conformation in this region.  
Our model provides an explanation why 
immunization against the CFH-AA site could 
occur only in CFHR1-deficient individuals only 
since in normal individuals the presence of 
CFHR1 with an epitope similar to the 
hypothetical induced autoantigenic conformation 
of CFH would have guaranteed tolerance to that 
conformation of CFH. The model proposed here 
can explain also the other key biological 
phenomena described in autoimmune aHUS: 
association with infections (14,46), clustering of 
the autoantibody epitopes on domain 20 of CFH 
(Fig. 1), autoantibodies of IgG or IgA class (9,26) 
since foreign peptide for T-cell help could be 
provided by the microbial protein inducing the 
autoantigenic conformation, and polyclonality of 
the autoimmune response (23) since different 
epitopes on the autoantigenic loop could be 
recognized by various B-cell receptors. 
In this report we show that CFH-AAs 
bind to a common site on the loop R1182-L1189 
of CFH next to the buried two residues different 
in CFH19-20 and CFHR14-5. The crystal structure 
of CFHR14-5 presented here also showed that the 
conformation of the autoantigenic loop is 
different on CFH and CFHR1. Taken together 
these data provided the basis for the suggested 
novel model (Fig. 5) to explain how CFHR1 
deficiency is linked to CFH-AA formation.  
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(arnab.bhattacharjee@helsinki.fi) or M.J. (mihaly.jozsi@gmx.net) 
 
The  abbreviations  used  are:  aHUS,  atypical  hemolytic  uremic  syndrome;  A I - a H U S ,  
a u t o i m m u n e  atypical  hemolytic  uremic  syndrome; CCP,  complement control  protein  
domain;  CFH,  complement  factor  H;  CFHR1,  complement  factor  H-related protein-1; CFH-
AA, anti-CFH autoantibodies; WT, wild type. 
 
FIGURE LEGENDS 
 
FIGURE 1. Mapping of CFH-AA binding region on domains 19-20 of CFH. (A) Binding of IgG from 
seventeen aHUS patients and a monoclonal anti-CFH antibody C18 to 14 CFH19-20 constructs with 
various single point mutations in relation to binding to the WT CFH19-20. The error bars indicate 
standard error of the mean and the level of WT binding is indicated by a dotted line. (B) Comparison 
of the autoantibody binding epitopes by identification of the mutations that impaired binding of patient 
IgG at least by 30% (indicated by ‘’). (C) Location of the residues involved in binding of 
autoantibodies to CFH19-20 as indicated in dark grey and annotated on a previously published structure 
of CFH19-20 (PDB code 2G7I)(7); location of W1183 is indicated with stripes. (D) For comparison, 
location of the residues involved in binding of CFH19-20 to heparin(5,40), and (E) location of the 
residues involved in the common microbial binding site on CFH19-20 (30) are indicated in dark grey. 
 
FIGURE 2. Binding of autoantibodies from autoimmune aHUS patients to CFH and CFHR1. (A) 
Binding of the autoantibodies to CFH (full length) and its fragments CFH1-7, CFH8-14, CFH15-20, and 
CFH19-20. (B) Binding of the IgG autoantibodies to CFH, CFHR1 (full length), CFHR14-5, and 
CFHR4B (full length). Human serum albumin (HSA) and/or normal human serum (NHS) were used as 
negative controls and polyclonal goat anti-CFH antibody as a positive control. (C) A bar diagram 
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elucidating the relative binding ratio of the patient autoantibodies to CFH19-20 and CFHR14-5. The error 
bars indicate the standard error of the mean. CFHR1 deficiency of each patient is shown below the 
columns of panel C. (D) Binding of purified IgG from the patient 11 to CFH19-20 was tested in the 
presence of increasing concentration of CFH19-20 or CFHR14-5. CFH5-7 was used as a negative control. 
(E) Bar diagram of the concentration of CFH19-20 or CFHR14-5 needed for 50% inhibition (IC50) 
obtained from three independent experiments performed in triplicates. The error bars indicate the 
standard error of the mean. 
 
FIGURE 3. Crystal structure of CFHR14-5 and its comparison with the previously solved structure of 
CFH19-20. (A) Structural superposition of the two molecules of CFHR14-5 (orange and yellow) found in 
the asymmetric unit along with CFH19-20 (grey) shown in a cartoon model. (B) Comparison of the 
surface charge potentials of CFHR14-5 and CFH19-20. Potentials on the solvent accessible surfaces were 
calculated and displayed at ±2 kT/e level on both the structures after modeling all of the missing side 
chains of the previously published structure of CFH19-20 (PDB code 2G7I)(7). (C) A close view of the 
two residues different in the amino acid sequences of these two protein constructs with the 2mFo-DFc 
electron density map of CFHR14-5 shown. (D) A close view of the region in which the tertiary 
structures of CFHR14-5 and CFH19-20 were dissimilar (residues R1182 through L1189 of CFH19-20 and 
the corresponding residues R281 through L288 of CFHR14-5) with backbone and side chain atoms 
shown using a stick model. This region corresponds to the CFH-AA binding site shown in Fig. 1. (E) 
A cartoon representation of the structural superposition of CFHR14-5 (orange: PDB code 4MUC) with 
CFH19-20 (grey: PDB code 2G7I (7)), CFH19-20 in complex with a sialic acid glycan and C3d (slate: 
PDB code 4ONT (21)),  and CFH19-20 in complex with OspE (turquoise: PDB code 4J38 (29)). (F) A 
close view of the residues R1182 through L1189 of CFH19-20 and the corresponding homologous 
residues of CFHR14-5 with a color scheme same as seen in Figure 3, E. 
 
FIGURE 4. Comparison of the models and 2mFo-DFc electron density maps of the CFH-AA binding 
site of CFH19-20 and the corresponding site of CFHR14-5. (A) The CFHR14-5 loop region (R281-L288), 
or (B) the CFH19-20 loop region (R1182-L1189) are shown with the CFHR14-5 2mFo-DFc electron 
density map. (C) The CFH19-20 loop region (R1182-L1189), or (D) the CFHR14-5 loop region (R281-
L288) are shown with the CFH19-20 2mFo-DFc electron density map.  Stick model and electron density 
map of CFHR14-5 are displayed in orange and those of CFH19-20 in grey. 
 
FIGURE 5. A schematic illustration of a model to explain the occurrence of CFH-AA in aHUS with 
special attention to the strong association of autoimmune aHUS with homozygous deficiency of 
CFHR1. In the upper part of the figure phenotype of normal and CFHR1 deficient individuals are 
shown schematically to indicate the structural difference observed between the CFH-AA site and the 
corresponding site on CFHR1 (dark gray protrusion). In the novel “induced neoepitope model” binding 
of a ligand to domain 20 of CFH, such as a microbial protein, induces a conformational change in the 
loop R1182-L1189 of the domain 20 thereby making its conformation similar to that on CFHR1 
domain 5.  
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